GENINCODE PLC LS -01 (9PL) - Total Liabilities
Based on the latest financial reports, GENINCODE PLC LS -01 (9PL) has total liabilities worth €1.56 Million EUR (≈ $1.82 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore GENINCODE PLC LS -01 cash conversion from operations to assess how effectively this company generates cash.
GENINCODE PLC LS -01 - Total Liabilities Trend (2021–2024)
This chart illustrates how GENINCODE PLC LS -01's total liabilities have evolved over time, based on quarterly financial data. Check GENINCODE PLC LS -01 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
GENINCODE PLC LS -01 Competitors by Total Liabilities
The table below lists competitors of GENINCODE PLC LS -01 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Alliance Developpement Capital SIIC SE
PA:ALDV
|
France | €16.86 Million |
|
Aurora Energy Metals Ltd
AU:1AE
|
Australia | AU$208.63K |
|
National Plastic Co Ltd Preferred
KO:004255
|
Korea | ₩168.34 Billion |
|
Spago Nanomedical AB
ST:SPAGO
|
Sweden | Skr5.94 Million |
|
Truscreen Group Ltd
AU:TRU
|
Australia | AU$951.80K |
Liability Composition Analysis (2021–2024)
This chart breaks down GENINCODE PLC LS -01's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see GENINCODE PLC LS -01 (9PL) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.59 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GENINCODE PLC LS -01's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GENINCODE PLC LS -01 (2021–2024)
The table below shows the annual total liabilities of GENINCODE PLC LS -01 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €1.54 Million ≈ $1.80 Million |
-46.98% |
| 2023-12-31 | €2.90 Million ≈ $3.39 Million |
-25.66% |
| 2022-12-31 | €3.90 Million ≈ $4.56 Million |
+161.19% |
| 2021-12-31 | €1.49 Million ≈ $1.74 Million |
-- |
About GENINCODE PLC LS -01
GENinCode Plc develops and commercializes clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally. Its predictive technology offers patients and physicians with preventative care and treatment strategies. The company's invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to prov… Read more